Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

TES HT100 Klinisk validering for hjerne-skade screening hos pasienter med lett hodeskade eller nevrologiske symptomer (TESCO)

21. september 2026 oppdatert av: B&B srl

TES HT100 Kliniske Resultater - Klinisk Validering av TES HT100 Temnograf for Hjerneskade Screening hos Pasienter med Lett Hodeskade eller Mistenkte Nevrologiske Symptomer (TESCO)

The goal of this clinical study is to evaluate how accurately and safely the TES HT100 device can identify intracranial abnormalities in adult emergency department patients with mild head trauma or neurological symptoms that are not related to trauma and are not immediately life-threatening. The main questions it aims to answer are:

  • How well does TES HT100 identify patients with intracranial abnormalities compared with head CT, the reference standard?
  • Is TES HT100 safe to use in this patient population?
  • Could TES HT100 help improve patient triage and use of hospital resources in the emergency setting?

Researchers will compare the result of TES HT100 with the head CT report.

Participants will:

  • Be enrolled if they are adults presenting to the emergency department with mild head trauma or selected neurological symptoms
  • Undergo standard clinical assessment and head CT according to usual care
  • Have an additional TES HT100 examination lasting about 5 minutes, performed by trained personnel
  • Be assessed for device performance and any adverse events related to use of the device

Studieoversikt

Detaljert beskrivelse

This is a prospective, multicenter, open-label clinical investigation evaluating the TES HT100 as a non-invasive adjunctive screening device for detection of intracranial abnormalities in adult Emergency Department patients. The study is being conducted in three centers in Italy and Poland.

TES HT100 is intended for non-invasive detection of endocerebral lesions. The device used in this investigation is TES HT model 100, equipped with software version 1.3 or later and firmware version 1.4 or later, in the same configuration planned for commercialization. The system uses non-ionizing, ultra-low-power electromagnetic waves in the 500-6500 MHz frequency range and provides a binary result indicating the presence or absence of intracranial abnormality. The examination is brief, with an overall duration of about 5 minutes.

The study is designed to evaluate the diagnostic performance and safety of TES HT100 when used in addition to standard emergency care. Participants undergo routine clinical assessment and brain CT according to usual clinical practice, and the TES HT100 examination is performed as an add-on procedure. The reference standard for performance evaluation is the brain CT report. TES HT100 is not intended to replace standard clinical assessment or CT imaging.

To reduce interpretation bias, the TES HT100 examination is performed by trained personnel who do not have access to the CT report at the time of testing, and the radiologist interpreting the CT scan is blinded to the TES HT100 result. TES HT100 examinations are performed within 24 hours before or after CT, according to site workflow.

The investigation plans to enroll approximately 850 participants overall across two clinical cohorts. The study duration is planned to be 30 months. Three TES HT100 devices, one per participating center, will be used under the same qualification and maintenance procedures.

In addition to diagnostic validation against CT, the study includes safety monitoring during device use and an exploratory assessment of the potential clinical utility of TES HT100 in emergency department triage and resource management. The overall objective is to generate clinical evidence on the performance and safety of TES HT100 as a rapid, non-invasive screening support tool in the emergency setting.

Studietype

Intervensjonell

Registrering (Antatt)

850

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • CE
      • Castel Volturno, CE, Italia, 81030
        • Rekruttering
        • Pineta Grande Hospital
        • Ta kontakt med:
        • Underetterforsker:
          • Angelo Localzo, Registered Nurse
        • Underetterforsker:
          • Esaù Russo, Registered Nurse
        • Hovedetterforsker:
          • Adriana Modestina Conte, MD
        • Underetterforsker:
          • Antonia Sorbo, MD - Radiologist
      • Gdansk, Polen, 80-952
        • Har ikke rekruttert ennå
        • Emergency Department, University Clinical Centre, Medical University of Gdańsk
        • Ta kontakt med:
        • Hovedetterforsker:
          • Mariusz Siemiński, prof. dr hab. n. med.
      • Katowice, Polen, 40-635
        • Rekruttering
        • Emergency Department, Leszek Giec Upper Silesian Medical Centre of the Medical University of Silesia in Katowice
        • Ta kontakt med:
        • Hovedetterforsker:
          • Mateusz Majewski, dr n. med.

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Age greater than 18 years
  • Provision of informed consent
  • Presentation to the Emergency Department with mild head injury, or
  • Presentation to the Emergency Department for non-traumatic neurological symptoms and not in a critical condition, including:
  • syncope
  • spatial disorientation and/or loss of balance
  • speech disturbance and/or facial hemi-paresis
  • visual alterations
  • memory loss and/or confusional state

Exclusion Criteria:

  • Age less than 18 years
  • Pregnant women
  • Metal plates or metal prostheses installed in the skull cap
  • Severe head trauma and/or extensive lacerated-contused areas
  • Critical condition
  • Visible skull fracture
  • Failure or inability to provide signed informed consent

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Diagnostisk
  • Tildeling: N/A
  • Intervensjonsmodell: Enkeltgruppeoppdrag
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: TES HT100 Examination

All enrolled participants receive standard emergency department evaluation, including head CT according to usual clinical practice, and undergo an additional TES HT100 examination as an add-on procedure. TES HT100 is evaluated against the head CT report used as the reference standard. The study includes adults with mild head injury and adults with neurological symptoms not related to head trauma and not in a critical or life-threatening condition.

A non-invasive, add-on diagnostic examination performed with the TES HT100 device to assess the presence or absence of intracranial abnormality in adult emergency department patients. The device uses ultra-low-power, non-ionizing electromagnetic waves in the 500-6500 MHz range and provides a binary on/off result. The examination lasts about 5 minutes, does not require direct contact with the patient's head, and is performed by trained personnel in addition to standard clinical evaluation and head CT.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Diagnostic accuracy of TES HT100 for detection of intracranial abnormalities
Tidsramme: At the index emergency department visit, with TES HT100 performed within 24 hours before or after head CT

Diagnostic performance of TES HT100 compared with the head CT report as the reference standard, assessed by ROC-AUC and by sensitivity and specificity for identification of intracranial abnormalities.

At the index emergency department visit, with TES HT100 performed within 24 hours before or after head CT
Rate of device-related adverse events
Tidsramme: From TES HT100 examination through study participation completion, an average of 1 year

Incidence and type of adverse events related to the use of TES HT100 during the study.

From TES HT100 examination through study participation completion, an average of 1 year

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Operator time associated with TES HT100-supported screening
Tidsramme: Day 1

Descriptive evaluation of operator time associated with use of TES HT100 during emergency department screening, based on the number of TES HT100 examinations performed per participant and the approximate duration of each examination (about 5 minutes), as described in the protocol.

Day 1
Procedures associated with TES HT100-supported screening
Tidsramme: Day 1

Descriptive evaluation of workflow-related procedures associated with use of TES HT100 during emergency department screening, as part of the exploratory assessment of potential clinical benefit described in the protocol. This may include patient handling or organizational procedures required during the diagnostic pathway, such as patient transfer to a different bed or room or need for additional staff support.

Day 1
Costs associated with TES HT100-supported screening
Tidsramme: Day 1

Descriptive evaluation of resource use and related cost considerations associated with use of TES HT100 during emergency department screening, as part of the exploratory assessment of potential clinical benefit described in the protocol.

Day 1
Diagnostic performance of TES HT100 in predefined patient subgroups
Tidsramme: At the index emergency department visit, with TES HT100 performed within 24 hours before or after head CT

Analysis of TES HT100 diagnostic performance, based on sensitivity and specificity versus head CT, in predefined subgroups, including younger patients, older patients, patients with or without prior injury or brain surgery, and patients with or without neurodegenerative disease.

At the index emergency department visit, with TES HT100 performed within 24 hours before or after head CT

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Etterforskere

  • Studieleder: Fabrizio Alfieri, B&B srl

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Generelle publikasjoner

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

4. desember 2024

Primær fullføring (Antatt)

30. desember 2026

Studiet fullført (Antatt)

30. januar 2027

Datoer for studieregistrering

Først innsendt

14. mars 2026

Først innsendt som oppfylte QC-kriteriene

18. mars 2026

Først lagt ut (Faktiske)

24. mars 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

24. september 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

21. september 2026

Sist bekreftet

1. september 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

De-identified participant-level data may be shared upon reasonable request, subject to ethics and institutional approval where applicable and execution of a data sharing agreement. Public sharing is not planned due to confidentiality and consent restrictions.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere